Antibody Licensing Opportunities From a One-of-a-Kind Discovery Engine
Antibodies continue to expand the boundaries of druggable targets and treatable diseases. Yet bringing a biologic to market, even one that promises to be first- or best-in-class, is filled with preclinical and clinical obstacles that can’t be overcome alone.
At Twist Biopharma Solutions, we're seeking partnerships with academic, biotech, and biopharma teams to help us translate lead assets from our unique discovery and optimization platform into clinical successes. Through close collaboration, we can break the shackles off of hard-to-drug targets in strategic therapeutic areas, ensuring that no disease is labeled “untreatable” and no patient is left behind.
Our Therapeutic Focus
With our discovery, optimization, and characterization capabilities as our foundation, we’ve made expanding your pipeline in important indications simple.
Immuno-oncology
Metabolic Disease
Rare Disease
Oncology
Inflammation
Cardiovascular Disease
Our Asset Pipeline
Our pipeline is dedicated to tackling challenging targets and discovering high-potential assets with promising pharmacology. With our end-to-end antibody development capabilities, we’ve assembled promising preclinical data packages to springboard you into the clinic.
Schedule a meeting to learn more about our flexible partnering options and data packages for asset licensing.
Why partner with Twist?
Robust Preclinical Data Packages
We’ve generated favorable binding, functional, and in vivo data for many of our lead antibody agonists, antagonists, and binders, giving you a head start on pre-clinical development and validation.
Derisked and Vetted by Our Experts
Our high-throughput developability workflow and comprehensive screening by our internal team of antibody experts ensures that we’ve mitigated developability risks as much as possible.
Best-in-Class Discovery and Optimization
Our lead assets were discovered and optimized using our unique, high-diversity phage display libraries and mouse-based platforms that explore only the most promising, relevant sequence space.
Flexible Design and Collaboration
Many of our leads are fully-humanized IgG antibodies or VHH nanobodies. Our antibody expertise, base-by-base DNA writing capabilities, and flexible partnership accelerate the development of bispecific antibodies or other therapeutic classes.
Interested in hearing more about our unique antibody licensing opportunities?
Partner with Twist Biopharma Solutions to shape the future of antibody therapeutics. Our de-risked preclinical assets bring promise and potential to your pipeline. They are the product of our best-in-class discovery, optimization, and characterization platforms. See how we can help unlock new opportunities and strategic positioning in biopharma.
Get in Touch With Us
Antibody enthusiasts are standing by and would love to hear more about your discovery needs. Challenging targets welcome!
